In8Bio (INAB) Short term Debt (2020 - 2021)
In8Bio (INAB) posted Short term Debt of $174000.0 for Q2 2021, little changed sequentially from $174000.0 in Q4 2020.
In8Bio (INAB) Short term Debt (2020 - 2021) Analysis & Trends
In8Bio has reported Short term Debt for 2 years, with the latest figure at $174000.0 in Q2 2021.
- Quarterly Short term Debt changed N/A year-over-year to $174000.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $174000.0 (changed N/A YoY) and the FY2020 annual result came in at $174000.0, changed N/A from the prior year.
- Short term Debt was little changed at $174000.0 in Q2 2021 per INAB's latest filing, from $174000.0 in the prior quarter.
- Over five years, Short term Debt peaked at $174000.0 in Q4 2020 and troughed at $174000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | In8Bio | 22.97 Mn | 22.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 174,000.00 |
| Dec 31, 2020 | 174,000.00 |